{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:07Z","timestamp":1792755907626,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Kaiser Permanente Southern California"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased gonorrhea incidence. Although a gonorrhea-specific vaccine does not exist, N. gonorrhoeae shares much of its genome with Neisseria meningitidis, notably critical antigenic determinants including outer membrane vesicles (OMV). Prior observational studies have suggested that OMV-based meningococcal serogroup B vaccines confer protection against gonorrhea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a matched cohort study from 2016 to 2020 to examine the association of OMV-containing recombinant meningococcal serogroup B vaccine (4CMenB) with gonorrhea infection among teens and young adults at Kaiser Permanente Southern California. Recipients of 4CMenB were matched in a ratio of 1:4 to recipients of non\u2013OMV-containing polysaccharide-conjugate vaccine targeting serotypes A, C, W, and Y (MenACWY) who had not received 4CMenB and were followed for incident gonorrhea. We used Cox proportional hazards regression to compare gonorrhea rates among recipients of 4CMenB vs MenACWY, adjusting for potential confounders. We conducted the same analysis with chlamydia as a negative control outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 6641 recipients of 4CMenB matched to 26 471 recipients of MenACWY. During follow-up, gonorrhea incidence rates per 1000 person-years (95% confidence intervals [CIs]) were 2.0 (1.3\u20132.8) for recipients of 4CMenB and 5.2 (4.6\u20135.8) for recipients of MenACWY. In adjusted analyses, gonorrhea rates were 46% lower among recipients of 4CMenB vs MenACWY (hazard ratio [HR], 0.54; 95% CI, .34\u2013.86), but chlamydia rates were similar between vaccine groups (HR, 0.98; 95% CI, .82\u20131.17).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest cross-protection of 4CMenB against gonorrhea, supporting the potential for vaccination strategies to prevent gonorrhea.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac436","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:32:29Z","timestamp":1654072349000},"page":"e1341-e1349","source":"Crossref","is-referenced-by-count":100,"title":["Prevention of <i>Neisseria gonorrhoeae<\/i> With Meningococcal B Vaccine: A Matched Cohort Study in Southern California"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8277-2431","authenticated-orcid":false,"given":"Katia J","family":"Bruxvoort","sequence":"first","affiliation":[{"name":"Department of Epidemiology, University of Alabama at Birmingham , Birmingham, Alabama , USA"},{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Lewnard","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, School of Public Health, University of California\u2013Berkeley , Berkeley, California , USA"},{"name":"Division of Infectious Diseases & Vaccinology, School of Public Health, University of California\u2013Berkeley , Berkeley, California , USA"},{"name":"Center for Computational Biology, College of Engineering, University of California\u2013Berkeley , Berkeley, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie H","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Fu","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California , USA"},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine , Pasadena, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Los Angeles Medical Center, Southern California Permanente Medical Group , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Veltman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Loma Linda University Health School of Medicine , Loma Linda, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Marrazzo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham Heersink School of Medicine , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California , Pasadena, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2023020817092512900_ciac436-B1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMp1812269","article-title":"Neisseria gonorrhoeae\u2014rising infection rates, dwindling treatment options","volume":"379","author":"Blank","year":"2018","journal-title":"N Engl J Med"},{"key":"2023020817092512900_ciac436-B2","volume-title":"Sexually Transmitted Disease Surveillance 2018","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2023020817092512900_ciac436-B3","volume-title":"Sexually Transmitted Disease Surveillance 2020","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2023020817092512900_ciac436-B4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/OLQ.0000000000001382","article-title":"Estimates of the prevalence and incidence of chlamydia and gonorrhea among US men and women, 2018","volume":"48","author":"Kreisel","year":"2021","journal-title":"Sex Transm Dis"},{"key":"2023020817092512900_ciac436-B5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/infdis\/jiy551","article-title":"Azithromycin susceptibility among Neisseria gonorrhoeae isolates and seasonal macrolide use","volume":"219","author":"Olesen","year":"2019","journal-title":"J Infect Dis"},{"key":"2023020817092512900_ciac436-B6","doi-asserted-by":"crossref","first-page":"e52307","DOI":"10.7554\/eLife.52307","article-title":"Potential impact of outpatient stewardship interventions on antibiotic exposures of common bacterial pathogens","volume":"9","author":"Tedijanto","year":"2020","journal-title":"Elife"},{"key":"2023020817092512900_ciac436-B7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC\u2019s treatment guidelines for gonococcal infection, 2020","volume":"69","author":"St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023020817092512900_ciac436-B8","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.15585\/mmwr.mm6949a5","article-title":"Notes from the field: first case in the United States of Neisseria gonorrhoeae harboring emerging mosaic penA60 allele, conferring reduced susceptibility to cefixime and ceftriaxone","volume":"69","author":"Picker","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023020817092512900_ciac436-B9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/infdis\/jiab581","article-title":"A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men","volume":"225","author":"Hui","year":"2021","journal-title":"J Infect Dis"},{"key":"2023020817092512900_ciac436-B10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023020817092512900_ciac436-B11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","article-title":"Vaccines against gonorrhea: current status and future challenges","volume":"32","author":"Jerse","year":"2014","journal-title":"Vaccine"},{"key":"2023020817092512900_ciac436-B12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/sti.79.2.124","article-title":"Gonorrhoea reinfection in heterosexual STD clinic attendees: longitudinal analysis of risks for first reinfection","volume":"79","author":"Mehta","year":"2003","journal-title":"Sex Transm Infect"},{"key":"2023020817092512900_ciac436-B13","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1172\/JCI114040","article-title":"Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection","volume":"83","author":"Plummer","year":"1989","journal-title":"J Clin Invest"},{"issue":"1","key":"2023020817092512900_ciac436-B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/vaccines7010005","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"2023020817092512900_ciac436-B15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2023020817092512900_ciac436-B16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"2023020817092512900_ciac436-B17","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1074\/mcp.M116.058800","article-title":"Proteomics-driven antigen discovery for development of vaccines against gonorrhea","volume":"15","author":"Zielke","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"2023020817092512900_ciac436-B18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023020817092512900_ciac436-B19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)30017-5","article-title":"Pitfalls of the healthy vaccinee effect","volume":"391","author":"Mahmud","year":"2018","journal-title":"Lancet"},{"key":"2023020817092512900_ciac436-B20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40471-018-0148-x","article-title":"The replication crisis in epidemiology: snowball, snow job, or winter solstice?","volume":"5","author":"Lash","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"2023020817092512900_ciac436-B21","doi-asserted-by":"crossref","first-page":"e2005203","DOI":"10.1371\/journal.pbio.2005203","article-title":"The importance of being second","volume":"16","author":"PloS Biology Staff Editors","year":"2018","journal-title":"PLOS Biol"},{"key":"2023020817092512900_ciac436-B22","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2023020817092512900_ciac436-B23","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023020817092512900_ciac436-B24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023020817092512900_ciac436-B25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/cid\/ciy548","article-title":"Epidemiology of meningococcal disease outbreaks in the United States, 2009\u20132013","volume":"68","author":"Mbaeyi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023020817092512900_ciac436-B26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2023020817092512900_ciac436-B27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1514866","article-title":"Immunogenicity of a meningococcal B vaccine during a university outbreak","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"2023020817092512900_ciac436-B28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7812\/TPP\/12-031","article-title":"Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data","volume":"16","author":"Koebnick","year":"2012","journal-title":"Perm J"},{"key":"2023020817092512900_ciac436-B29","volume-title":"American Community Survey, 2019 American Community Survey 5-year estimates 2015\u20132019","author":"US Census Bureau","year":"2020"},{"key":"2023020817092512900_ciac436-B30","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/QAI.0000000000002668","article-title":"Referral linkage to preexposure prophylaxis care and persistence on preexposure prophylaxis in an integrated health care system","volume":"87","author":"Bruxvoort","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023020817092512900_ciac436-B31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"2023020817092512900_ciac436-B32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"2023020817092512900_ciac436-B33","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"2023020817092512900_ciac436-B34","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/21645515.2017.1381810","article-title":"Impact of meningococcal group B OMV vaccines, beyond their brief","volume":"14","author":"Petousis-Harris","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2023020817092512900_ciac436-B35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of infants with meningococcal group B vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"2023020817092512900_ciac436-B36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"2023020817092512900_ciac436-B37","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1073\/pnas.93.20.11109","article-title":"Analysis of the genetic differences between Neisseria meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two different pathogenicities","volume":"93","author":"Tinsley","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023020817092512900_ciac436-B38","doi-asserted-by":"crossref","first-page":"e01668-19","DOI":"10.1128\/mBio.01668-19","article-title":"Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine","volume":"10","author":"Marjuki","year":"2019","journal-title":"mBio"},{"issue":"21","key":"2023020817092512900_ciac436-B39","doi-asserted-by":"publisher","first-page":"00812","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","volume":"S1473-3099","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"2023020817092512900_ciac436-B40","doi-asserted-by":"publisher","first-page":"00754","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","volume":"S1473-3099","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac436\/48613706\/ciac436.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e1341\/49125412\/ciac436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e1341\/49125412\/ciac436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:48:38Z","timestamp":1675878518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/e1341\/6596517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac436","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,6,1]]}}}